Eli Lilly, compounding and drug Zepbound
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
Hims & Hers (HIMS) stock falls 8% as court denies injunction on FDA ruling for Eli Lilly's (LLY) Zepbound shortage. Read more ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback